701 related articles for article (PubMed ID: 36115852)
1. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.
Yang Y; Li S; Wang Y; Zhao Y; Li Q
Signal Transduct Target Ther; 2022 Sep; 7(1):329. PubMed ID: 36115852
[TBL] [Abstract][Full Text] [Related]
2. Advances in studies of tyrosine kinase inhibitors and their acquired resistance.
Jiao Q; Bi L; Ren Y; Song S; Wang Q; Wang YS
Mol Cancer; 2018 Feb; 17(1):36. PubMed ID: 29455664
[TBL] [Abstract][Full Text] [Related]
3. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
Yin Y; Yuan X; Gao H; Yang Q
Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
[TBL] [Abstract][Full Text] [Related]
4. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.
Kim M; Baek M; Kim DJ
Curr Pharm Des; 2017 Nov; 23(29):4226-4246. PubMed ID: 28625132
[TBL] [Abstract][Full Text] [Related]
5. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
6. Reversing multidrug resistance by tyrosine kinase inhibitors.
He M; Wei MJ
Chin J Cancer; 2012 Mar; 31(3):126-33. PubMed ID: 22237041
[TBL] [Abstract][Full Text] [Related]
7. Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors.
Tullemans BME; Heemskerk JWM; Kuijpers MJE
J Thromb Haemost; 2018 Sep; 16(9):1686-1699. PubMed ID: 29975003
[TBL] [Abstract][Full Text] [Related]
8. EGFR-TKIs resistance via EGFR-independent signaling pathways.
Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
Shukla S; Chen ZS; Ambudkar SV
Drug Resist Updat; 2012; 15(1-2):70-80. PubMed ID: 22325423
[TBL] [Abstract][Full Text] [Related]
10. FGFR-TKI resistance in cancer: current status and perspectives.
Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
12. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
13. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.
Anreddy N; Gupta P; Kathawala RJ; Patel A; Wurpel JN; Chen ZS
Molecules; 2014 Sep; 19(9):13848-77. PubMed ID: 25191874
[TBL] [Abstract][Full Text] [Related]
16. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
Smith CIE
Semin Cancer Biol; 2017 Aug; 45():36-49. PubMed ID: 27865897
[TBL] [Abstract][Full Text] [Related]
17. Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors.
Filippi I; Naldini A; Carraro F
Curr Med Chem; 2011; 18(19):2885-92. PubMed ID: 21651491
[TBL] [Abstract][Full Text] [Related]
18. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Noda S; Kanda S
Expert Rev Respir Med; 2016; 10(5):547-56. PubMed ID: 26959310
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.
Krchniakova M; Skoda J; Neradil J; Chlapek P; Veselska R
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365759
[TBL] [Abstract][Full Text] [Related]
20. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.
Kuwano M; Sonoda K; Murakami Y; Watari K; Ono M
Pharmacol Ther; 2016 May; 161():97-110. PubMed ID: 27000770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]